Invitrogen’s SelectScreen profiling and screening service integrates enzyme collections and cell-lines with state-of-the-art bioassay technologies to accelerate drug discovery programs.
Alan Drummond, chief scientific officer of Chroma, said: “Invitrogen’s large panel of kinases allows us to determine whether our candidate drugs are inhibiting the appropriate kinases and how they interact with other kinases, enabling us to predict potential side effects or new indications.”